News Conference News TCT 2017 Long-term Absorb BVS Data Continue to Disappoint Michael O'Riordan October 31, 2017
News Daily News Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond Michael O'Riordan October 17, 2017
News Daily News Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force Michael O'Riordan October 11, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2017 Shelley Wood September 30, 2017
News Features Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen? Michael O'Riordan September 13, 2017
News Daily News Boston Scientific Scraps Biodegradable Scaffold Program Michael O'Riordan August 01, 2017
News Conference News EuroPCR 2017 DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit Michael O'Riordan May 16, 2017
News Features Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions Michael O'Riordan May 08, 2017
News Features Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe Shelley Wood May 05, 2017
News Daily News Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance Michael O'Riordan April 18, 2017
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS Michael O'Riordan March 18, 2017
News Conference News CRT 2017 Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate Michael O'Riordan February 21, 2017
News Daily News DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed Michael O'Riordan February 16, 2017